Plozasiran Cuts Pancreatitis Events in High Triglyceride Trials

Pooled phase 3 data from 757 adults show the investigational siRNA therapy reduced acute pancreatitis events versus placebo.

Updated on Nov. 9, 2026 in Diabetes

Plozasiran Cuts Pancreatitis Events in High Triglyceride Trials

A pooled analysis of the SHASTA-3 and SHASTA-4 phase 3 trials found plozasiran reduced acute pancreatitis events by 78% compared with placebo in adults with triglycerides of 500 mg/dL or higher. The analysis was presented at the American Heart Association Scientific Sessions 2026.

Why it matters

Severe hypertriglyceridemia can trigger acute pancreatitis, a potentially serious inflammatory condition, and the data suggest a targeted therapy may lower that risk. The pooled results add evidence on an apolipoprotein C3-directed approach for patients with very high triglyceride levels.

The pooled analysis of 757 adults randomized 2:1 to plozasiran 25 mg or placebo found a 4.1% absolute risk reduction for acute pancreatitis, with a number needed to treat of 24. Serious treatment-emergent adverse events occurred in 8.3% of plozasiran patients versus 10% on placebo, while worsening glycemic control was reported more often on plozasiran (14% vs. 8.7%).

The players

American Heart Association

The American Heart Association is a major U.S. nonprofit focused on cardiovascular research, education, and public health advocacy.

The details

Plozasiran is a small interfering RNA that targets apolipoprotein C3, and the SHASTA-3 and SHASTA-4 trials were global, double-blind, placebo-controlled studies in which patients received subcutaneous plozasiran or placebo every three months. Treatment-emergent adverse events occurred in 73% of patients in both groups, and 1.2% discontinued due to adverse events.

Timeline

  1. August 2026: Topline SHASTA-3 and SHASTA-4 results were reported, showing approximately 80% triglyceride reductions.

  2. November 7, 2026: The pooled pancreatitis analysis was presented at the AHA Scientific Sessions 2026 in Chicago, Illinois.

Health Landscape

The SHASTA-3 and SHASTA-4 program extends the topline triglyceride-lowering results reported in August 2026 to a clinical endpoint, acute pancreatitis. This moves the evidence for plozasiran from biomarker reduction toward outcomes that matter to patients with severe hypertriglyceridemia.

Patients with severe hypertriglyceridemia may eventually have a treatment option aimed at lowering pancreatitis risk, though the therapy is investigational. The trial data also report a higher rate of worsening glycemic control on plozasiran, a factor clinicians and patients would need to weigh.

The takeaway

Lowering triglycerides is one piece of managing pancreatitis risk, and the pooled data show a meaningful absolute reduction in events. Patients should discuss any emerging therapy and its trade-offs, including glycemic effects, with their clinicians.

Further reading

For broader context on metabolic conditions linked to high triglycerides, explore Diabetes coverage.